Search news
Most searched tags
Bayer Material Science derives Occupational Exposure Limit for Multi-Wall Carbon Nanotubes
On the 16th November 2009, Bayer Material Science (BMS) announced that it has derived an Occupational Exposure Limit (OEL) for multi-wall carbon nanotubes: OEL was set at 0.05 mg/m³. The press release describes how BMS ‘recently implemented a product stewardship program to ensure the safe use of its products. Baytubes, BMS multi-wall carbon nanotubes, have also been part of this program. The latest results of sub-chronic inhalation studies support the conclusion that Baytubes act like poorly soluble particles.’ According to BMS, the derived OEL was ‘[b]ased on previous single and recent repeated inhalation studies BMS just derived an Occupational Exposure Limit (OEL). [...] The detailed results of the inhalation studies have been recently published in the peer-reviewed journals “Inhalation Toxicology”, “Toxicological Sciences” and “Toxicology”.’
Follow this link to read the full Bayer Material Science press release.
Related Links:
On the 1st December 2009, the Nanotechnology Industries Association (NIA) started a new project that aims to review and collate exposure information on nanomaterials under REACH. (16th December 2009)
US EPA is proposing a Significant New Use Rules (SNURs) for single- and multi-walled carbon nanotubes; according to a Notice in the US Federal Register (6th November 2009), ‘[t]he two substances are identified generically as multi-walled carbon nanotubes (P–08– 177) and single-walled carbon nanotubes (P–08–328). These substances are subject to TSCA section 5(e) consent orders issued by EPA. [...]’ (6th November 2009)
The US National Institute for Occupational Safety and Health’s (NIOSH) has published a notice of recent accomplishments in NIOSH’s research and collaboration programme on the occupational safety and health implications and applications of nanotechnology: [...]. (13th August 2009)
Following the publication of a study suggesting that multi-walled carbon nanotubes follow a ‘fibre paradigm’ (i.e. fibres of a specific aspect ratio (i.e. length/diameter) and morphology can cause the same kind of clinical symptoms as those observed for other fibres of a similar morphology and aspect ratio), Matthew Dalton investigates for The Wall Street Journal, how nanotechnology will be regulated under REACH, the new European chemical legislation that comes into force on the 1st June 2008. (29th May 2008)